Cell BioEngines is a NYC-based clinical-stage biotech focused on developing allogeneic 'off-the-shelf' stem cell-derived therapies as cell-based 'drugs' for human disease. It leverages a proprietary platform that uses universal, non-gene-modified donor blood stem cells obtained from umbilical cord to produce clinical-grade cells at scale. The company’s lead program, CBE-101, is an expanded cord blood-derived hematopoietic cell therapy intended as an alternative for hematological cancer patients who cannot find a donor. Led by CEO Dr. Ajay Vishwakarma, Cell BioEngines aims to deliver off-the-shelf cell therapies and is positioning CBE-101 for multicenter clinical testing. The company said it will use newly raised funds to expand operations and its R&D sector. The article reports the company raised an additional $2M in the latest funding update.

Total raised

$2M

Funding rounds

1

Latest round

Equity

Latest activity

Jul 2024